[go: up one dir, main page]

HUP0002514A2 - [5-Aril-2-(aril-amino)-fenil]-ecetsavak és származékaik - Google Patents

[5-Aril-2-(aril-amino)-fenil]-ecetsavak és származékaik

Info

Publication number
HUP0002514A2
HUP0002514A2 HU0002514A HUP0002514A HUP0002514A2 HU P0002514 A2 HUP0002514 A2 HU P0002514A2 HU 0002514 A HU0002514 A HU 0002514A HU P0002514 A HUP0002514 A HU P0002514A HU P0002514 A2 HUP0002514 A2 HU P0002514A2
Authority
HU
Hungary
Prior art keywords
alkyl
derivatives
certain
arylaminophenylacetic acids
arylaminophenylacetic
Prior art date
Application number
HU0002514A
Other languages
English (en)
Inventor
Roger Aki Fujimoto
Leslie Wighton Mcquire
Benjamin Biro Mugrage
Daqiang Xu
John Henry Van Duzer
Original Assignee
Novartis Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26736901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0002514(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag. filed Critical Novartis Ag.
Publication of HUP0002514A2 publication Critical patent/HUP0002514A2/hu
Publication of HUP0002514A3 publication Critical patent/HUP0002514A3/hu
Publication of HU225774B1 publication Critical patent/HU225774B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A találmány szelektív ciklooxigenáz-2 (COX-2) inhibitorokkéntalkalmazható (I) általános képletű vegyületekre - amelyek képletében Rjelentése metil- vagy etilcsoport; R1 jelentése klór- vagy fluoratom;R2 jelentése hirogén-, fluor-, klóratom, metil-, etil-, metoxi-,etoxi- vagy hidroxicsoport; R3 jelentése hidrogén- vagy fluoratom; ésRq jelentése klór-, fluoratom, trifluor-metil- vagy metilcsoport - ésgyógyászatilag elfogadható sóikra, valamint gyógyászatilag elfogadhatóprodrog észtereikre vonatkozik. Ó
HU0002514A 1997-08-28 1998-08-26 Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives, method for their preparation, pharmaceutical compositions comprising thereof and their use HU225774B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5780397P 1997-08-28 1997-08-28
US6983797P 1997-08-28 1997-08-28
PCT/EP1998/005414 WO1999011605A1 (en) 1997-08-28 1998-08-26 Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives

Publications (3)

Publication Number Publication Date
HUP0002514A2 true HUP0002514A2 (hu) 2000-12-28
HUP0002514A3 HUP0002514A3 (en) 2002-11-28
HU225774B1 HU225774B1 (en) 2007-08-28

Family

ID=26736901

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0002514A HU225774B1 (en) 1997-08-28 1998-08-26 Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives, method for their preparation, pharmaceutical compositions comprising thereof and their use

Country Status (34)

Country Link
US (5) US6291523B1 (hu)
EP (1) EP1007505B1 (hu)
JP (1) JP3704470B2 (hu)
KR (1) KR100637296B1 (hu)
CN (1) CN1140500C (hu)
AR (1) AR015157A1 (hu)
AT (1) ATE237580T1 (hu)
AU (1) AU743371B2 (hu)
BR (1) BR9812010B1 (hu)
CA (1) CA2298033C (hu)
CO (1) CO4960662A1 (hu)
CY (1) CY2007020I2 (hu)
CZ (1) CZ298522B6 (hu)
DE (4) DE122007000035I1 (hu)
DK (1) DK1007505T3 (hu)
ES (1) ES2197508T3 (hu)
FR (1) FR09C0011I2 (hu)
HU (1) HU225774B1 (hu)
ID (1) ID23953A (hu)
IL (2) IL134498A0 (hu)
LU (2) LU91346I2 (hu)
MY (1) MY127881A (hu)
NL (1) NL300379I2 (hu)
NO (2) NO326196B1 (hu)
NZ (1) NZ502669A (hu)
PE (1) PE108099A1 (hu)
PL (1) PL194480B1 (hu)
PT (1) PT1007505E (hu)
RU (1) RU2186762C2 (hu)
SI (1) SI1007505T1 (hu)
SK (1) SK283773B6 (hu)
TR (1) TR200000447T2 (hu)
TW (1) TWI250142B (hu)
WO (1) WO1999011605A1 (hu)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
ATE284691T1 (de) * 1998-11-02 2005-01-15 Merck & Co Inc Zusammensetzungen aus einem 5ht1b/1d agonisten und einem selektiven cox-2 hemmer zur behandlung von migräne
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
US20040053900A1 (en) * 1998-12-23 2004-03-18 Pharmacia Corporation Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
GB9922830D0 (en) 1999-09-27 1999-11-24 Novartis Ag Processes
DE60016191T2 (de) 1999-12-08 2005-12-22 Pharmacia Corp., Chicago Cyclooxygenase-2 hemmer enthaltende zusammensetzungen mit schnellem wirkungseintritt
AR030630A1 (es) * 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas
AU2001216038A1 (en) * 2000-11-14 2002-05-27 Alcon Laboratories Inc. Treatment of glaucoma and ocular hypertension
US7656959B2 (en) 2001-04-13 2010-02-02 Agere Systems Inc. Pipelined decision-feedback unit in a reduced-state viterbi detector with local feedback
US20050264906A1 (en) * 2004-05-25 2005-12-01 Haratsch Erich F Method and apparatus for reduced-state Viterbi detection in a read channel of a magnetic recording system
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
DE10129320A1 (de) * 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
PE20030323A1 (es) * 2001-08-31 2003-05-12 Novartis Ag Composicion farmaceutica
BR0212435A (pt) 2001-09-10 2004-08-17 Sugen Inc Derivados de 3-(4,5,6,7-tetraidroindol-2-ilmetilideno)-2-indolinona como inibidores de cinase
US7288246B2 (en) * 2001-09-13 2007-10-30 The Board Of Regents Of The University Of Oklahoma Method of alleviating chronic pain via peripheral glutaminase regulation
US7504231B2 (en) * 2001-09-13 2009-03-17 The Board Of Regents Of The University Of Oklahoma Method of alleviating chronic pain via peripheral inhibition of neurotransmitter synthesis
GB0124459D0 (en) * 2001-10-11 2001-12-05 Novartis Ag Organic compounds
DK1441714T3 (da) * 2001-10-25 2008-03-31 Novartis Ag Kombinationer omfattende en selektiv cyclooxygenase-2-inhibitor
DE60217895T2 (de) * 2001-11-06 2007-07-05 Novartis Ag Kombination cyclooxygenase-2 inhibitor/ histone deacetylase inhibitor
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
GB0201520D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Pharmaceutical uses
CA2476744A1 (en) * 2002-03-07 2003-09-12 Novartis Ag Solid pharmaceutical compositions comprising lumiracoxib
GB0209257D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US7220749B2 (en) * 2002-06-11 2007-05-22 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
ITMI20021391A1 (it) 2002-06-25 2003-12-29 Nicox Sa Nitroderivati di inibitori della cicloossigenasi-2
EP2319493A3 (en) 2002-07-23 2011-07-27 Novartis AG Ophthalmic ointment composition comprising a drug, an ointment base and a solubilizing/dispersing agent
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
AU2003294221A1 (en) * 2002-09-13 2004-04-19 Kenneth E. Miller Method of alleviating pain via inhibition of neurotransmitter synthesis
GB0224198D0 (en) * 2002-10-17 2002-11-27 Novartis Ag Organic compounds
US7632866B2 (en) * 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
PE20040844A1 (es) 2002-11-26 2004-12-30 Novartis Ag Acidos fenilaceticos y derivados como inhibidores de la cox-2
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
WO2004054575A1 (en) * 2002-12-18 2004-07-01 Novartis Ag Combinations of valsartan with cox-2 inhibitors
US7157577B2 (en) 2003-03-07 2007-01-02 Sugen Inc. 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
TWI327913B (en) * 2003-03-12 2010-08-01 Novartis Ag Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
US20050159403A1 (en) * 2003-04-22 2005-07-21 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of central nervous system damage
WO2004093813A2 (en) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
US20040229803A1 (en) * 2003-04-22 2004-11-18 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders
WO2004093814A2 (en) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a sodium channel blocker
PL1534305T3 (pl) 2003-05-07 2007-03-30 Osteologix As Leczenie zaburzeń chrząstek i kości solami strontu rozpuszczalnymi w wodzie
US20050107387A1 (en) * 2003-05-13 2005-05-19 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders
WO2004103286A2 (en) * 2003-05-14 2004-12-02 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a cholimergic agent
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
WO2004105699A2 (en) * 2003-05-28 2004-12-09 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
US20050101597A1 (en) * 2003-07-10 2005-05-12 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitior and a non-NMDA glutamate modulator for the treatment of central nervous system damage
WO2005009342A2 (en) * 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
WO2005009354A2 (en) * 2003-07-17 2005-02-03 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an ikk inhibitor for the treatment of ischemic-mediated central nervous system disorders or injury
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
WO2005018563A2 (en) * 2003-08-22 2005-03-03 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
WO2005023189A2 (en) * 2003-09-03 2005-03-17 Pharmacia Corporation Method of cox-2 selective inhibitor and nitric oxide-donating agent
BRPI0414956A (pt) * 2003-10-03 2006-11-14 Pharmacia Corp composições de um inibidor seletivo da ciclooxigenase-2 administradas sob condições hipotérmicas para o tratamento de distúrbios ou lesões do sistema nervoso central mediados por isquemia
BRPI0415111A (pt) * 2003-10-08 2006-11-28 Novartis Ag composição farmacêutica que compreende o ácido 5-metil-2-( 2`-cloro-6`-fluoroanilino) fenilacético
WO2005046615A2 (en) * 2003-11-12 2005-05-26 Pharmacia & Upjohn Company Llc Compositions for treatment of central nervous system mediated disorders
WO2005066214A1 (ja) 2004-01-07 2005-07-21 Seikagaku Corporation ヒアルロン酸誘導体及びそれを含む薬剤
RU2412686C2 (ru) * 2004-03-23 2011-02-27 Новартис Аг Фармацевтические композиции
TW200603792A (en) * 2004-04-23 2006-02-01 Pharmacia & Upjohn Co Llc Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
US7487432B2 (en) * 2004-05-25 2009-02-03 Agere Systems Inc. Method and apparatus for multiple step Viterbi detection with local feedback
US7653154B2 (en) * 2004-05-25 2010-01-26 Agere Systems Inc. Method and apparatus for precomputation and pipelined selection of intersymbol interference estimates in a reduced-state Viterbi detector
US7380199B2 (en) * 2004-05-25 2008-05-27 Agere Systems Inc. Method and apparatus for precomputation and pipelined selection of branch metrics in a reduced-state Viterbi detector
GB0415320D0 (en) * 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0416508D0 (en) * 2004-07-23 2004-08-25 Merck Sharp & Dohme Therapeutic agents
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
DE102004044827A1 (de) * 2004-09-16 2006-03-23 Bayer Cropscience Ag Jod-phenylsubstituierte cyclische Ketoenole
AR051966A1 (es) 2004-11-23 2007-02-21 Astrazeneca Ab Derivados de acido fenoxiacetico utiles para el tratamiento de enfermedades respiratorias
AU2005318372A1 (en) 2004-12-23 2006-06-29 Glaxo Group Limited Pyridine compounds for the treatment of prostaglandin mediated diseases
MX2007010186A (es) * 2005-02-22 2007-11-06 Merial Ltd Metodos para tratar selectivamente desordenes mediados por cox-2 mediante la administracion de gamma-tocoferol.
MX2007013304A (es) 2005-04-26 2007-12-13 Pfizer Anticuerpos de p-caderina.
AU2006244393B2 (en) * 2005-05-05 2012-06-21 Cook Biotech Incorporated Implantable materials and methods for inhibiting tissue adhesion formation
PL2447283T3 (pl) 2005-09-07 2015-12-31 Amgen Fremont Inc Ludzkie przeciwciała monoklonalne przeciwko kinazie podobnej do receptora aktywiny-1 (ALK-1)
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
WO2007039736A1 (en) 2005-10-06 2007-04-12 Astrazeneca Ab Novel compounds
JP2007275193A (ja) * 2006-04-04 2007-10-25 Fujifilm Corp 光プローブおよび光断層画像化装置
AR061623A1 (es) * 2006-06-26 2008-09-10 Novartis Ag Derivados de acido fenilacetico
GB0704407D0 (en) 2007-03-07 2007-04-18 Glaxo Group Ltd Compounds
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
US7943658B2 (en) * 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
EP2203411B1 (en) 2007-09-20 2016-01-06 Ramot at Tel-Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
US20090082452A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lumiracoxib
EP2257524B1 (en) 2008-02-01 2016-01-06 Brickell Biotech, Inc. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
JP2011512359A (ja) 2008-02-14 2011-04-21 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体のアンタゴニストとしての環式ジアリールエーテル化合物
JP2011513242A (ja) 2008-02-25 2011-04-28 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体アンタゴニスト
US8426449B2 (en) 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
US20110190227A1 (en) 2008-07-03 2011-08-04 Amira Pharmaceuticals, Inc. Antagonists of Prostaglandin D2 Receptors
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
EP2177215A1 (en) 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and NSAIDs
WO2010056741A2 (en) * 2008-11-12 2010-05-20 Auspex Pharmaceuticals, Inc. Phenylacetic acid inhibitors of cyclooxygenase
WO2010057118A2 (en) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
WO2011012622A1 (en) 2009-07-30 2011-02-03 Glaxo Group Limited Benzoxazinone derivatives for the treatment of glytl mediated disorders
US8785393B2 (en) 2009-07-31 2014-07-22 Panmira Pharmaceuticals, Llc Ophthalmic pharmaceutical compositions of DP2 receptor antagonists
MX2012001542A (es) 2009-08-05 2012-06-19 Panmira Pharmaceuticals Llc Antagonista dp2 y usos del mismo.
WO2011023753A1 (en) 2009-08-27 2011-03-03 Glaxo Group Limited Benzoxazine derivatives as glycine transport inhibitors
PH12012501349A1 (en) * 2010-01-06 2013-01-14 Panmira Pharmaceuticals Llc Dp2 antagonist and uses thereof
GB201000685D0 (en) 2010-01-15 2010-03-03 Glaxo Group Ltd Novel compounds
GB201007789D0 (en) 2010-05-10 2010-06-23 Glaxo Group Ltd Novel Compound
GB201007791D0 (en) 2010-05-10 2010-06-23 Glaxo Group Ltd Novel compounds
JP5815029B2 (ja) 2010-07-09 2015-11-17 クオンベルゲンセ プハルマセウトイカルス リミテッド カルシウムチャネル遮断薬としてのテトラゾール化合物
RU2439053C1 (ru) * 2010-08-03 2012-01-10 Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет" Диариламины и способ их получения
US8892989B1 (en) * 2010-08-26 2014-11-18 Clearslide, Inc. Method for searching companies and people
US8900798B2 (en) 2010-10-18 2014-12-02 Eastman Kodak Company On-press developable lithographic printing plate precursors
US20120090486A1 (en) 2010-10-18 2012-04-19 Celin Savariar-Hauck Lithographic printing plate precursors and methods of use
US20120141942A1 (en) 2010-12-03 2012-06-07 Domenico Balbinot Method of preparing lithographic printing plates
US20120141941A1 (en) 2010-12-03 2012-06-07 Mathias Jarek Developing lithographic printing plate precursors in simple manner
US20120141935A1 (en) 2010-12-03 2012-06-07 Bernd Strehmel Developer and its use to prepare lithographic printing plates
WO2012098400A1 (en) 2011-01-19 2012-07-26 Convergence Pharmaceuticals Limited Piperazine derivatives as cav2.2 calcium channel blockers
US20120199028A1 (en) 2011-02-08 2012-08-09 Mathias Jarek Preparing lithographic printing plates
EA026702B1 (ru) 2011-09-16 2017-05-31 Санофи Производные анилина, их получение и терапевтическое применение
US8632941B2 (en) 2011-09-22 2014-01-21 Eastman Kodak Company Negative-working lithographic printing plate precursors with IR dyes
US9029063B2 (en) 2011-09-22 2015-05-12 Eastman Kodak Company Negative-working lithographic printing plate precursors
CN102311355B (zh) * 2011-09-26 2014-02-05 扬州天和药业有限公司 罗本考昔的一种制备方法
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
US8679726B2 (en) 2012-05-29 2014-03-25 Eastman Kodak Company Negative-working lithographic printing plate precursors
US9063423B2 (en) 2013-02-28 2015-06-23 Eastman Kodak Company Lithographic printing plate precursors and use
US9201302B2 (en) 2013-10-03 2015-12-01 Eastman Kodak Company Negative-working lithographic printing plate precursor
GB201417499D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417497D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417500D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
US11583516B2 (en) 2016-09-07 2023-02-21 Trustees Of Tufts College Dash inhibitors, and uses related thereto
MY195178A (en) 2017-03-14 2023-01-11 Seikagaku Kogyo Co Ltd Composition for Treating Joint Disease and Kit Containing Same
CN117427183A (zh) 2017-03-14 2024-01-23 生化学工业株式会社 关节疾病处置用组合物及含有其的试剂盒
KR102069205B1 (ko) * 2017-08-09 2020-01-22 연성정밀화학(주) 라타노프로스틴 부노드의 제조 방법 및 그를 위한 중간체
CN109694330B (zh) * 2017-10-24 2023-10-20 乳源瑶族自治县东阳光生物科技有限公司 一种酸的制备方法
EP3830072A1 (en) 2018-07-27 2021-06-09 KRKA, d.d., Novo mesto A process for the preparation of polymorphic form of robenacoxib
CN109503399B (zh) * 2018-12-29 2021-12-24 江苏天和制药有限公司 一种罗本考昔的制备方法
CN110437090A (zh) * 2019-07-31 2019-11-12 江苏天和制药有限公司 一种罗本考昔三聚体及其制备方法
CN111807978B (zh) * 2020-07-29 2023-03-14 武汉川泰科技有限公司 一种罗贝考昔的制备方法
WO2022195579A1 (en) 2021-03-15 2022-09-22 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases
EP4281183A4 (en) 2022-03-23 2025-07-02 Alivira Animal Health Ltd IMPROVED PROCESS FOR PURIFICATION OF ROBENACOXIB
CN120004366B (zh) * 2025-04-18 2025-07-25 浙江九安检测科技有限公司 一种二噁英前处理过程中有机试剂的回收方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558690A (en) 1965-04-08 1971-01-26 Gelgy Chemical Corp Substituted derivatives of 2-anilinophenylacetic acids and a process of preparation
US3895063A (en) 1965-04-08 1975-07-15 Ciba Geigy Corp Substituted Anilino Benzyl Alcohols
GB1166861A (en) 1966-01-15 1969-10-15 Aspro Nicholas Ltd New Diphenylamine Derivatives and Compositions containing them
US3652762A (en) 1970-04-14 1972-03-28 Ciba Geigy Corp Pharmaceutical compositions and methods employing substituted derivatives of 2-anilinophenylacetic acids and esters
US4173577A (en) 1970-09-09 1979-11-06 Ciba-Geigy Corporation Phenylacetohydroxamic acids
ES520813A0 (es) 1983-03-21 1984-05-16 Prodes Sa Procedimiento para la obtencion del ester del acido 2-(2,6-diclorofenil)amino bencenoacetico con acido glicolico.
DE3445011A1 (de) 1983-12-13 1985-06-13 Ciba-Geigy Ag, Basel Neues anilinderivat, verfahren zu seiner herstellung und seine verwendung
GR900100380A (el) * 1989-05-20 1991-10-10 Fisons Plc Μέ?οδος παρασκευής αντι-φλεγμονωδών παραγώγων αμινοφενόλης.
IT1256345B (it) 1992-08-20 1995-12-01 Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione
JPH11505503A (ja) 1994-06-29 1999-05-21 ノバルティス アクチェンゲゼルシャフト 有機塩基カチオンとの２−〔（２，６−ジクロロフェニル）アミン〕フェニルアセトキシ酢酸の新規の塩類
JPH0977664A (ja) 1995-09-13 1997-03-25 Yakult Honsha Co Ltd シクロオキシゲナーゼ−２特異的阻害剤及び抗炎症剤
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados

Also Published As

Publication number Publication date
RU2186762C2 (ru) 2002-08-10
US7115662B2 (en) 2006-10-03
AU9534098A (en) 1999-03-22
US6310099B1 (en) 2001-10-30
ES2197508T3 (es) 2004-01-01
FR09C0011I1 (hu) 2009-04-17
JP2001514244A (ja) 2001-09-11
US20020183391A1 (en) 2002-12-05
US6727281B2 (en) 2004-04-27
TWI250142B (en) 2006-03-01
EP1007505B1 (en) 2003-04-16
DE122007000035I1 (de) 2007-07-19
CY2007020I1 (el) 2012-01-25
AU743371B2 (en) 2002-01-24
ATE237580T1 (de) 2003-05-15
SK283773B6 (sk) 2004-01-08
WO1999011605A8 (en) 2000-03-02
HK1031374A1 (en) 2001-06-15
IL134498A (en) 2009-06-15
US6451858B2 (en) 2002-09-17
MY127881A (en) 2006-12-29
DE122009000013I1 (de) 2009-06-25
NO2009007I1 (no) 2009-04-06
NO2009007I2 (no) 2010-06-07
HUP0002514A3 (en) 2002-11-28
ID23953A (id) 2000-06-08
DE69813570D1 (de) 2003-05-22
PE108099A1 (es) 1999-11-18
DK1007505T3 (da) 2003-07-21
NZ502669A (en) 2002-02-01
KR20010023344A (ko) 2001-03-26
WO1999011605A1 (en) 1999-03-11
SK2472000A3 (en) 2000-09-12
PL338357A1 (en) 2000-10-23
BR9812010B1 (pt) 2010-12-14
EP1007505A1 (en) 2000-06-14
LU91346I2 (fr) 2007-09-11
NL300379I1 (nl) 2009-05-06
KR100637296B1 (ko) 2006-10-23
US20040122254A1 (en) 2004-06-24
NL300379I2 (nl) 2010-02-01
JP3704470B2 (ja) 2005-10-12
CN1268112A (zh) 2000-09-27
LU91540I2 (fr) 2009-05-11
CO4960662A1 (es) 2000-09-25
PL194480B1 (pl) 2007-06-29
CA2298033A1 (en) 1999-03-11
US20020013369A1 (en) 2002-01-31
HU225774B1 (en) 2007-08-28
NO20000943D0 (no) 2000-02-25
US6291523B1 (en) 2001-09-18
CZ2000714A3 (cs) 2000-06-14
AR015157A1 (es) 2001-04-18
BR9812010A (pt) 2000-12-12
CA2298033C (en) 2007-10-02
TR200000447T2 (tr) 2000-07-21
FR09C0011I2 (hu) 2011-04-01
DE69813570T2 (de) 2004-02-12
SI1007505T1 (en) 2003-10-31
NO326196B1 (no) 2008-10-13
PT1007505E (pt) 2003-08-29
DE122007000035I2 (de) 2010-07-01
CZ298522B6 (cs) 2007-10-24
NO20000943L (no) 2000-02-25
CY2007020I2 (el) 2012-01-25
IL134498A0 (en) 2001-04-30
CN1140500C (zh) 2004-03-03

Similar Documents

Publication Publication Date Title
HUP0002514A2 (hu) [5-Aril-2-(aril-amino)-fenil]-ecetsavak és származékaik
DK0620215T3 (da) 1H-indol-3-acetamidderivater som sPLA2-inhibitorer
AU2507088A (en) Amino acid derivatives of phosphorus acids
HUP9802517A2 (hu) Foszfonsavval helyettesített benzazepinon-N-ecetsav-származékok, eljárás ezek előállítására és az e vegyületeket tartalmazó gyógyászati készítmények
PT92378A (pt) Processo para a preparacao de derivados de cromano, activos sobre o sistema nervoso central
EP1186603A3 (en) Processes for preparing endothelin antagonists
AU565400B2 (en) 2-azaspiro(4 )-3-carboxylic acid derivatives
HUP0303166A2 (hu) Eljárás 2-(6-helyettesített 1,3-dioxán-4-il)-ecetsav-származékok előállítására
PT918776E (pt) Sintese total de acilfulvenos antitumorais
ATE149164T1 (de) Neue tetrazolderivate, verfahren zu ihrer herstellung und ihre verwendung
TW355709B (en) Quinoline carboxylic acid derivative
AR042404A2 (es) Compuestos derivados de anilina
DE60020130D1 (de) Verfahren zur herstellung 3-amino-gallensaurer derivate
DK1205476T3 (da) Fremgangsmåde til syntese af N-(mercaptoacyl)-aminosyrederivater ud fra alfa-substituerede acrylsyrer
MXPA04003086A (es) Proceso para sintesis estereoselectiva de 2-hidroximetil-cromanos.
DK0471493T3 (da) N,N,N-Trisubstituerede-5-bisaminomethylen-1,3-dioxan-4,6-dioner som inhibitorer af acyl-CoA:cholesterol-acyltransferase
ZA8312B (en) Substituted 1-benzoyl-2-phenyliminiomidazolidine derivatives
ECSP982641A (es) Ciertos acidos 5 - alquil-2-arilaminofenilaceticos y sus derivados
ZA9610804B (en) 4-Imidazolidinone compound process for its preparation and the pharmaceutical compositions which contain it
DE3481059D1 (de) Neue 11-piperazinyl-5h-imidazo(2,1-c)(1,4)benzodiazepine, verfahren zu ihrer herstellung und zwischenprodukte und erstere enthaltende arzneimittel.
DK0531119T3 (da) N,N,N-trisubstituerede 5-bis-aminomethylen-1,3-dioxan-4,6-dioner som inhibitorer af acyl-CoA: cholesterol-acyltransferase
TW358087B (en) Method for preparing carbamoylmethylurea derivatives
GB2282810A (en) Process for the preparation of clavulanic acid
JPS5427594A (en) Penicillin derivative
TW353064B (en) Process for the production of 2,4,4'-trichloro-2'-hydroxydiphenylether and esters thereof

Legal Events

Date Code Title Description
AA1S Information on application for a supplementary protection certificate

Free format text: PRODUCT NAME: ROBENACOXIB /ONSIOR/ OR IT'S SALT FOR VETERINARY USE OR PRODRUG; REG. NO/DATE: EU/2/08/089/001-020 20081217

Spc suppl protection certif: S0900007

Filing date: 20090410

Expiry date: 20180826

FG4S Grant of supplementary protection certificate

Free format text: PRODUCT NAME: ROBENACOXIB /ONSIOR/ OR IT'S SALT FOR VETERINARY USE OR PRODRUG; REG. NO/DATE: EU/2/08/089/001-020 20081217

Spc suppl protection certif: S0900007

Filing date: 20090410

Expiry date: 20180826

Extension date: 20230826

FH91 Appointment of a representative

Free format text: FORMER REPRESENTATIVE(S): PARRAGH GABORNE DR., S.B.G. & K. BUDAPESTI NEMZETKOEZI SZABADALMI IRODA, HU

Representative=s name: SBGK SZABADALMI UEGYVIVOEI IRODA, HU

FH92 Termination of representative

Representative=s name: PARRAGH GABORNE DR., S.B.G. & K. BUDAPESTI NEM, HU

GB9A Succession in title

Owner name: NOVARTIS TIERGESUNDHEIT AG, CH

Free format text: FORMER OWNER(S): NOVARTIS AG., CH

HC9A Change of name, address

Owner name: ELANCO TIERGESUNDHEIT AG, CH

Free format text: FORMER OWNER(S): NOVARTIS AG., CH; NOVARTIS TIERGESUNDHEIT AG, CH